Reply

We thank the authors for their interest in our prospective study of aspirin use in patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD).1 The authors highlight that in addition to aspirin, weight loss is a central component of cardiovascular risk reduction, and this in turn can directly influence NAFLD histology. To that end, we would like to emphasize 3 important aspects of our study population and design. First,

Source: Clinical Gastroenterology and Hepatology - July 24, 2019 Category: Gastroenterology Authors: Tracey G. Simon, Kathleen E. Corey Tags: Letter to the Editor Source Type: research